一年只要打6针！FDA刚批准皮炎新疗法，复发患者终于不用频繁跑医院了
07-04 19:19
精选参考来源
精选参考来源
1. 来瑞奇珠单抗
摩熵医药 2026-06-22 00:00:00
2. FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
Reportify 2026-06-10 00:00:00
3. Lilly Receives FDA Nod For EBGLYSS Eight-Week Subcutaneous Maintenance Dose In Atopic Dermatitis
Nasdaq 2026-06-10 00:00:00
已收藏
去我的收藏夹